Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
- NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2024.
- 11/08/2024
|
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
- NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, and Nobelpharma Co., Ltd. today announced that they have entered into an exclusive license and distribution agreement for the development and commercialization in Japan of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma.
- 11/04/2024
|
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
- YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/01/2024
|
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
- NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET.
- 10/25/2024
|
Y-mAbs to Participate in Upcoming Investor Conferences in October
- NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that its management team will participate in the following upcoming investor conferences:
- 10/01/2024
|
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
- NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented September 6 – 7, 2024, at the American Academy of Cancer Research (“AACR”) Special Conference in the Advances in Pediatric Cancer Research in Toronto, Canada.
- 09/06/2024
|
Y-mAbs to Participate in Upcoming Investor Conferences in September
- NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the following upcoming investor conferences:
- 09/03/2024
|
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
- The commercial-stage biotech took the wraps off its second-quarter results. Revenue was up on a year-over-year basis, but it fell short of analyst estimates -- as did net loss.
- 08/12/2024
|
Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
- YMAB maintains a market valuation around $500 million, potential for substantial appreciation. Pipeline updates include expanding the naxitamab market and progressing SADA radioimmunotherapeutic. Financially, YMAB has $77.8 million in cash, growing product revenues, and a cash runway of 8-9 quarters.
- 08/12/2024
|
Y-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Peter Pfreundschuh - CFO Conference Call Participants Etzer Darout - BMO Capital Markets Nicole Germino - Truist Securities Justin Walsh - JonesTrading Alec Stranahan - Bank of America Michael Ulz - Morgan Stanley John Newman - Canaccord Genuity Operator Good morning, and welcome to Y-mAbs Therapeutics Inc.'s Earnings Conference Call for the Second Quarter of 2024. At this time, all participants are in a listen-only mode.
- 08/12/2024
|
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
- Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago.
- 08/12/2024
|
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
- NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2024.
- 08/12/2024
|
Y-mAbs to Participate in Upcoming Investor Conferences in August
- NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences:
- 08/07/2024
|
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
- NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on Monday, August 12, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET.
- 08/05/2024
|
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB
- NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of stock of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB):
- 07/22/2024
|
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
- NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer.
- 07/01/2024
|
Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company's Long-Term Shareholders and Encourages Investors to Contact the Firm
- PHILADELPHIA, PA / ACCESSWIRE / June 14, 2024 / Kaskela Law LLC announces that it is investigating Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) ("Y-mAbs") on behalf of the company's long-term shareholders. Recently an amended securities fraud complaint was filed against Y-mAbs on behalf of certain investors who purchased shares of the company's stock between October 6, 2020, and October 28, 2022.
- 06/14/2024
|
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
- NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that preclinical GD2-SADA data will be presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting taking place June 8 – 11, 2024, in Toronto, Canada.
- 06/07/2024
|
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
- NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer.
- 06/05/2024
|
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
- NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL.
- 06/01/2024
|
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
- NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”) in patients with relapsed or refractory high-risk neuroblastoma with residual disease limited to bone and/or bone marrow. The results are summarized in poster presentations scheduled to be presented today, June 1, 2024, at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, IL.
- 06/01/2024
|
Y-mAbs Therapeutics, Inc. (YMAB) Q1 2024 Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-Investor Relations Michael Rossi - President and Chief Executive Officer Bo Kruse - Chief Financial Officer Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Bill Maughan - Canaccord Genuity Nick Unan - BMO Capital Markets David Nierengarten - Wedbush Securities Operator Good morning, and welcome to Y-mAbs Therapeutics Inc. Earnings Conference Call for the First Quarter of 2024. At this time, all participants are in a listen-only mode.
- 05/08/2024
|
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
- Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.15 per share a year ago.
- 05/07/2024
|
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
- The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET
- 04/26/2024
|
Y-mAbs to Present at 2024 ASCO Annual Meeting
- NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the acceptance of four abstracts at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.
- 04/25/2024
|
New Strong Buy Stocks for April 19th
- TCOM, YMAB, ZUO, DELL and AYI have been added to the Zacks Rank #1 (Strong Buy) List on April 19, 2023.
- 04/19/2024
|
New Strong Buy Stocks for April 17th
- BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
- 04/17/2024
|
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in YmAbs Therapeutics (YMAB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 03/28/2024
|
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
- YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 03/20/2024
|
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
- NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor. Mr. Kruse will remain in the Chief Financial Officer role until his successor is identified and joins the Company. He will then continue as a non-executive employee from the time his successor joins the Company through July 31, 2024, after which it is expected that Mr. Kruse will be available to the Company for a period of time to support a smooth transition of the Chief Financial Officer role.
- 03/14/2024
|
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
- The consensus price target hints at a 31.4% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 03/12/2024
|
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
- Does Y-mAbs Therapeutics, Inc. (YMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 03/05/2024
|
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
- Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development
- 03/04/2024
|
Y-mAbs Therapeutics, Inc. (YMAB) Q4 2023 Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (YMAB) Q4 2023 Earnings Call Transcript
- 03/01/2024
|
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
- Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.03 per share a year ago.
- 02/29/2024
|
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
- NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the quarter and full year ended December 31, 2023.
- 02/29/2024
|
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
- Y-mAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/22/2024
|
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
- NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, March 1, 2024, at 8:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Vignesh Rajah, Chief Medical Officer; Thomas Gad, Founder, Vice Chair and Chief Business Officer; and Steen Lisby, Chief Scientific Officer.
- 02/16/2024
|
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?
- Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 02/13/2024
|
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 5:15pm PT.
- 01/02/2024
|
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
- NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023.
- 12/13/2023
|
Y-mAbs Therapeutics, Inc. (YMAB) Q3 2023 Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q3 2023 Results Conference Call November 14, 2023 9:00 AM ET Company Participants Courtney Dugan - Vice President of Investor Relations Michael Rossi - President and Chief Executive Officer Thomas Gad - Chief Business Officer Bo Kruse - Chief Financial Officer Sue Smith - Chief Commercial Officer Steen Lisby - Chief Scientific Officer Conference Call Participants Alec Stranahan - Bank of America Charles Zhu - Guggenheim Bill Maughan - Canaccord Genuity Mike Ulz - Morgan Robert Burns - HC Wainwright Operator Good morning and welcome to Y-mAbs Therapeutics Third Quarter 2023 Earnings Conference Call. Please note that today's event is being recorded.
- 11/14/2023
|
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
- Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.63 per share a year ago.
- 11/13/2023
|
All You Need to Know About Y-mAbs Therapeutics, Inc. (YMAB) Rating Upgrade to Strong Buy
- Y-mAbs Therapeutics, Inc. (YMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 11/08/2023
|
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
- NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, November 14, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Thomas Gad, Founder, Vice Chair and Chief Business Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Steen Lisby, Chief Scientific Officer; and Vignesh Rajah, Chief Medical Officer.
- 10/31/2023
|
Y-mAbs: They Have Earnings, But Still Seek The Big Hit
- Y-mAbs Therapeutics is undervalued despite growing sales of their approved cancer therapy, presenting an opportunity for investors. Their approved product, naxitamab, has shown positive response rates in treating neuroblastoma. The company is also developing a multistep treatment approach called GD2-SADA, but its success is uncertain and requires further clinical evidence.
- 10/11/2023
|
Y-mAbs to Participate at Upcoming Investor Conferences in September
- NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Company will participate at the following upcoming investor conferences:
- 09/06/2023
|
Y-mAbs Therapeutics, Inc. (YMAB) Q2 2023 Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2023 Earnings Call Transcript August 11, 2023 9:00 AM ET Company Participants Courtney Dugan - Head of IR Thomas Gad - Founder, President & Interim CEO Vignesh Rajah - CMO Sue Smith - CCO Bo Kruse - CFO Conference Call Participants Alec Stranahan - Bank of America Charles Zhu - Guggenheim Securities Mike Ulz - Morgan Stanley Bill Maughan - Canaccord Genuity Tessa Romero - JP Morgan Luke Shumway - BMO Capital Markets Operator Good morning, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Conference Call for the Second Quarter of 2023. At this time, all participants are in a listen-only mode.
- 08/11/2023
|
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
- Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.94 per share a year ago.
- 08/10/2023
|
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
- NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, August 11, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, Founder, Chairman and Interim Chief Executive Officer, Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer, and Vignesh Rajah, Chief Medical Officer.
- 08/01/2023
|
Y-mAbs Therapeutics, Inc. (YMAB) Q1 2023 Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants Thomas Gad - Founder, President, Interim Chief Executive Officer Sue Smith - Senior Vice President and Chief Commercial Officer Vignesh Rajah - Senior Vice President and Chief Medical Officer Bo Kruse - Chief Financial Officer, Treasurer, and Secretary Conference Call Participants William Maughan - Canaccord Genuity Mike Ulz - Morgan Stanley Charles Zhu - Guggenheim Securities Tessa Romero - JP Morgan David Nierengarten - Wedbush Securities Operator Good morning, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Call for the First Quarter of 2023. At this time, all participants are in a listen-only mode.
- 05/14/2023
|
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
- Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.64 per share a year ago.
- 05/08/2023
|
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
- NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, May 9, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer.
- 04/28/2023
|
Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade
- The consensus price target hints at an 111.1% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 04/05/2023
|
Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains?
- Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 04/04/2023
|
Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates
- Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/30/2023
|
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
- NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, 2022, on Thursday, March 30, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, March 31, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer.
- 03/21/2023
|
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.
- 01/26/2023
|
Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
- NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its founder, President and Interim Chief Executive Officer, Thomas Gad, will provide an overview and update on the Company's business at the virtual 41st Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, January 11, 2023, at 5:15 PM Eastern Standard Time. The presentation can be accessed via a live audio webcast.
- 01/03/2023
|
Y-mAbs Therapeutics receives 'Neutral' stance from Wedbush after FDA rejection of its pediatric cancer drug application
- Broker Wedbush has repeated a 'neutral' stance on biopharma Y-mAbs Therapeutics Inc (NASDAQ:YMAB) following news that the US Food and Drug Administration (FDA) has turned down the company's application concerning a treatment for a rare form of nerve cancer in pediatric patients. On December 1, the company that the regulator had issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine 131I-omburtamab (omburtamab) to treat CNS/leptomeningeal metastasis from neuroblastoma.
- 12/02/2022
|
Y-mAbs Therapeutics, Inc. (YMAB) Q3 2022 Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q3 2022 Earnings Conference Call November 8, 2022 4:00 PM ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commercial Officer Bo Kruse - EVP, Secretary, Treasurer & CFO Conference Call Participants Alec Stranahan - Bank of America Merrill Lynch Etzer Darout - BMO Capital Markets William Maughan - Canaccord Genuity Edouard Mullarky - Guggenheim Securities Tessa Romero - JPMorgan Chase & Co. Sebastiaan van der Schoot - Kempen & Co. Joseph Thome - Cowen Operator Good afternoon, and welcome to the Y-mAbs Therapeutics, Inc. Earnings Conference Call for the Third Quarter of 2022. [Operator Instructions].
- 11/12/2022
|
3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240%
- Biotech penny stocks with upcoming events to watch in November 2022. The post 3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/09/2022
|
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates
- YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 16% and 7.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/07/2022
|
Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022
- NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended September 30, 2022, on Monday, November 7, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, November 8, 2022, at 4:00 p.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer and Vignesh Rajah, Chief Medical Officer.
- 11/02/2022
|
Y-mAbs Therapeutics shares fall 42% following last week's FDA advisory committee vote
- Shares of Y-mAbs Therapeutics Inc. YMAB, +0.90% plunged 42.5% in premarket trading on Monday after several banks downgraded the company's stock and a Food and Drug Administration advisory committee voted against approval of the company's experimental treatment for neuroblastoma patients. The committee on Friday voted 16-0 that there wasn't enough evidence to say that omburtamab improves overall survival.
- 10/31/2022
|
YmAbs Therapeutics, Inc. (YMAB) Soars 5.2%: Is Further Upside Left in the Stock?
- YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 09/29/2022
|
Y-mAbs Therapeutics, Inc. (YMAB) CEO Thomas Gad on Q2 2022 Results - Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2022 Results Conference Call August 9, 2022 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO and President Bo Kruse - CFO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Robert Burns - HC Wainwright Charles Zhu - Guggenheim Joseph Thome - Cowen & Company Tessa Romero - JP Morgan Mike Ulz - Morgan Stanley William Maughan - Canaccord Genuity Operator Good morning and welcome to the Y-mAbs Therapeutics, Inc., Earnings Conference Call for the Second Quarter 2022. Today's conference is being recorded.
- 08/12/2022
|
Y-mAbs Therapeutics, Inc. (YMAB) CEO Thomas Gad on Q1 2022 Results - Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2022 Results Conference Call May 10, 2022 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO and President Bo Kruse - CFO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Dr. Steen Lisby - Chief Scientific Officer Conference Call Participants Alec Stranahan - Bank of America Joseph Thome - Cowen & Company Charles Zhu - Guggenheim Mike Ulz - Morgan Stanley Tessa Romero - JP Morgan Sebastiaan van der Schoot - Kempen Operator Good day, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Conference Call for the First Quarter of 2022. Today's conference is being recorded.
- 05/14/2022
|
YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates
- YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/09/2022
|
Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022
- NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March 31, 2022 on Monday, May 9, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, May 10, 2022, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; and Sue Smith, Chief Commercial Officer.
- 05/03/2022
|
Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
- YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2022
|
Y-MAbs Therapeutics, Inc. (YMAB) CEO Claus Møller on Q4 2021 Results - Earnings Call Transcript
- Y-MAbs Therapeutics, Inc. (YMAB) CEO Claus Møller on Q4 2021 Results - Earnings Call Transcript
- 02/25/2022
|
YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates
- YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/24/2022
|
YmAbs Therapeutics, Inc. (YMAB) Soars 8.3%: Is Further Upside Left in the Stock?
- YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 02/01/2022
|
Y-mAbs Therapeutics, Inc.'s (YMAB) CEO Claus Moller on Q3 2021 Results - Earnings Call Transcript
- Y-mAbs Therapeutics, Inc.'s (YMAB) CEO Claus Moller on Q3 2021 Results - Earnings Call Transcript
- 11/05/2021
|
Y-mAbs Announces Data to be Presented at SIOP 2021
- NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to announce the acceptance of two presentations at the International Society of Pediatric Oncology (“SIOP”) Virtual Annual Congress held October 21 through October 24, 2021.
- 09/16/2021
|
Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China
- NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its partner SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has been granted priority review of the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma by the Center for Drug Evaluation (“CDE”) of China's National Medical Products Administration (“NMPA”).
- 09/13/2021
|
Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma
- NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a key opinion leader ("KOL") webinar on DANYELZA frontline and HITS data in high-risk neuroblastoma on Thursday, September 23, 2021 at 12 p.m. ET.
- 09/10/2021
|
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q2 2021 Results - Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
- YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 22.06% and 43.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Recap: Y-mAbs Therapeutics Q2 Earnings
- Shares of Y-mAbs Therapeutics (NASDAQ:YMAB) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 47.52% year over year to ($0.53), which beat the estimate of ($0.64).
- 08/05/2021
|
Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021
- NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, August 6, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.
- 07/29/2021
|
Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China
- NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has submitted the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the National Medical Products Administration (“NMPA”) of China.
- 07/06/2021
|
Y-mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA
- NEW YORK, June 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Committee for Orphan Medicinal Products (“COMP”) of the European Medicines Agency (“EMA”) has recommended the granting of orphan medicinal product designation (“OMPD”) in the European Union (“EU”) for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma. The positive opinion from the EMA's COMP has been sent to the European Commission (“EC”), which is expected to grant the orphan drug designation within 30 days.
- 06/25/2021
|
Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma
- NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Jaume Mora, M.D., Ph.D. from SJD Barcelona Children's Hospital will present frontline data for DANYELZA and GM-CSF for consolidation of high-risk neuroblastoma (“HR-NB”) patients in complete remission at the American Society of Clinical Oncology (“ASCO”) Virtual Annual Meeting on June 4, 2021
- 06/04/2021
|
Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America
- NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into an exclusive distribution agreement with Adium Pharma S.A. (“Adium”) to be the exclusive distributor in Latin America of the Company's antibodies, DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.
- 05/19/2021
|
Y-mAbs Announces Update on SADA Technology
- NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Nai-Kong V. Cheung, MD, PhD, Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center (“MSK”) will present a research update on the Company's SADA technology platform at PEGS Boston Virtual Conference on May 13, 2021 at 1:20 p.m. Eastern Time. The SADA technology was licensed by the Company from MSK and the Massachusetts Institute of Technology (“MIT”).
- 05/13/2021
|
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q1 2021 Results - Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer
- Y-mAbs Therapeutics Inc (NASDAQ: YMAB) recently concluded a Type B meeting with the FDA regarding omburtamab in CNS/leptomeningeal metastasis from neuroblastoma. The company received requests from the agency for additional data concerning the granularity of data from identified historical control groups.
- 04/20/2021
|
Y-mAbs Therapeutics' (YMAB) CEO Claus Moller on Q4 2020 Results - Earnings Call Transcript
- Y-mAbs Therapeutics' (YMAB) CEO Claus Moller on Q4 2020 Results - Earnings Call Transcript
- 02/26/2021
|
Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its public offering of 2,804,878 shares of its common stock, at a public offering price of $41.00 per share, which includes the exercise in full of the underwriters' option to purchase 365,853 additional shares of common stock. The aggregate gross proceeds to Y-mAbs, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $115 million. All of the shares of common stock were offered by the Company. Y-mAbs' common stock is listed on The Nasdaq Global Select Market under the ticker symbol "YMAB."
- 02/22/2021
|
Y-mAbs Therapeutics Raises $100M Via Equity To Fund Commercial Rollout Of Neuroblastoma Med
- Y-mAbs Therapeutics Inc (NASDAQ: YMAB) priced its public offering of 2.4 million common shares at $41 per share, for gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 365,853 shares.
- 02/18/2021
|
Y-mAbs Announces Pricing of Public Offering of Common Stock
- NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the pricing of its public offering of 2,439,025 shares of its common stock at a public offering price of $41.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100.0 million. All of the shares are being offered by Y-mAbs. In addition, Y-mAbs has granted the underwriters a 30-day option to purchase up to an additional 365,853 shares of common stock at the public offering price, less the underwriting discounts. The offering is expected to close on February 22, 2021, subject to the satisfaction of customary closing conditions.
- 02/17/2021
|
Y-mAbs Announces Sale of Priority Review Voucher
- NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (“PRV”) to United Therapeutics Corporation (Nasdaq: UTHR), based on an agreed valuation of $105 million.
- 12/28/2020
|
Y-mAbs Therapeutics: Further Upside After Approval
- Y-mAbs Therapeutics recently had its first approval. Its second drug, despite some hiccups, is on its way to the market.
- 12/21/2020
|
Week In Review: Week's China Life Science Investments Total $800 Million
- Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie.
- 12/20/2020
|
Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China
- NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a license agreement with SciClone Pharmaceuticals International Ltd (“SciClone”) to be the exclusive co-development and commercialization partner of the Company's antibodies, DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in China. DANYELZA (naxitamab-gqgk) 40mg/10mL was approved by the U.S. Food and Drug Administration (“FDA”) on November 25, 2020 and is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. The Company plans to resubmit its Biologics License Application (“BLA”) to the FDA for omburtamab by the end of 2020 or in early 2021.
- 12/18/2020
|
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe
- NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a distribution agreement with Swixx BioPharma AG (“Swixx”) to be the exclusive distributor of the Company's antibodies, DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in Eastern Europe, including Russia. DANYELZA (naxitamab-gqgk) 40mg/10mL was approved by the U.S. Food and Drug Administration (“FDA”) on November 25, 2020 and is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. The Company plans to resubmit its (“BLA”) to the FDA for omburtamab by the end of 2020 or in early 2021.
- 12/18/2020
|
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel
- NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer and Takeda Israel, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced today that they have entered into an exclusive license and distribution agreement for the registration and commercialization in Israel of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. DANYELZA (naxitamab-gqgk) was approved by the U.S. FDA on November 25, 2020. Additionally, Y-mAbs plans to resubmit the amended BLA for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma to the FDA by the end of 2020 or in early 2021.
- 12/04/2020
|
FDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
- NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has approved DANYELZA (naxitamab-gqgk) 40mg/10ml. DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval regulation based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA is a humanized, monoclonal antibody that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. DANYELZA is administered to patients three times in a week in an outpatient setting and the treatment is repeated every four weeks. The product has received Priority Review, Orphan Drug, Breakthrough Therapy, and Rare Pediatric Disease designations from the FDA.
- 11/25/2020
|
Y-mAbs Announces Update on Omburtamab in DIPG
- NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a clinical update on omburtamab for the treatment of diffuse intrinsic pontine glioma (“DIPG”). Data was presented at the Society for Neuro-Oncology (“SNO”) Virtual Annual Meeting held November 19 through November 21, 2020. The omburtamab data was presented by Dr. Evan Bander from Weill Cornell Medicine.
- 11/19/2020
|
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2020 Results - Earnings Call Transcript
- Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2020 Results - Earnings Call Transcript
- 11/08/2020
|
Y-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult Indications
- NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Company's Investigational New Drug (“IND”) application for 177Lu-omburtamab-DTPA for the treatment of B7-H3 positive Central Nervous System (“CNS”) and Leptomeningeal Metastasis (“LM”) from tumors in adult patients.
- 10/26/2020
|
